Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 3.14%
- Poor long term growth as Net Sales has grown by an annual rate of 16.24% and Operating profit at 7.86% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.01
Stock is technically in a Bearish range
Underperformed the market in the last 1 year
Stock DNA
Healthcare Services
INR 9 Cr (Micro Cap)
11.00
63
0.00%
-0.34
7.52%
0.84
Total Returns (Price + Dividend) 
Latest dividend: 0.4100 per share ex-dividend date: Sep-15-2011
Risk Adjusted Returns v/s 
Returns Beta
News

Dhanvantri Jeevan Rekha Ltd Downgraded to Strong Sell Amid Technical Weakness and Fundamental Concerns
Dhanvantri Jeevan Rekha Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 16 Nov 2026. This shift reflects a deterioration in technical indicators despite some positive quarterly financial results, highlighting concerns over the company’s long-term fundamentals and valuation metrics.
Read More
Dhanvantri Jeevan Rekha Ltd Downgraded to Sell Amid Weak Technicals and Fundamentals
Dhanvantri Jeevan Rekha Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Hold to Sell as of 1 October 2026. The revision reflects a combination of deteriorating technical indicators, weak long-term fundamentals, and valuation concerns despite recent positive quarterly financial results. This comprehensive analysis explores the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that have influenced the change in outlook for the stock.
Read More
Dhanvantri Jeevan Rekha Ltd Upgraded to Hold on Technical and Valuation Improvements
Dhanvantri Jeevan Rekha Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Sell to Hold as of 22 September 2026. This change reflects a notable improvement in the company’s technical indicators, valuation metrics, and recent financial performance, signalling a cautious but optimistic outlook for investors.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2026 | Source : BSEResult quater sept 2026
Board Meeting Outcome for Quarterly Result
13-Nov-2026 | Source : BSEQuarterly Result for 30.09.2026
Result
13-Nov-2026 | Source : BSEResult for quarter 30.09.2026
Corporate Actions 
No Upcoming Board Meetings
Dhanvantri Jeevan Rekha Ltd has declared 4% dividend, ex-date: 15 Sep 11
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Anil Elhence (6.76%)
Investor Education And Protection Fund (iepf) (6.74%)
50.56%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 46.75% vs 7.75% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 200.00% vs -182.35% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 2.07% vs 12.55% in Sep 2024
Growth in half year ended Sep 2025 is -124.24% vs 430.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 10.70% vs 11.91% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -81.25% vs 84.62% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 14.17% vs 10.65% in Mar 2025
YoY Growth in year ended Mar 2026 is -21.57% vs 200.00% in Mar 2025